Separating The Pork From The Lamb Grillers

Daniel George | May 20, 2019

Memorial Day weekend is soon, so I can’t resist the barbeque analogy. Honestly, have you ever seriously messed up grilling pork ribs? All you need to do is slather on some barbeque sauce, place them on a medium-low heat grill and crack open a beer. The last part is optional but regardless they almost always come out tasting great. A rack of lamb, by contrast, will have you minding over it, jockeying constantly between the flame and simmer and back again to perfect that crusty surface and juicy medium rare center.


Daniel George

Daniel George, MD is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine and leads the Duke Prostate and Urologic Cancer Center. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. Daniel George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006.

State-of-the-industry video lectures by leading urology experts
Everyday Urology - Oncology Insights
Publications focusing on urologic cancer treatments through original manuscripts
By William C. Carithers, Jr., PHD
Everyday Urology-Oncology Insights: Volume 2, Issue 2

Focusing on The First and Only FDA Approved Targeted  Alpha Therapy Radium-223 in the Treatment of mCRPC

The Tenth Symposium on Targeted Alpha Therapy (TAT-10) opened on Wednesday, May 31, 2017 in Kanazawa Japan. The symposium was jointly organized by the Joint Research Centre (JRC) of the European Commission and Kanazawa University as a forum for presentations on the latest developments in radiotherapy with alpha emitters in cancer. With over 200 participants the symposium covered advances in cancer treatment using alpha emitters as targeted therapy, clinical and preclinical research, radionuclide production, instrumentation and dosimetry.1
By Phillip J. Koo, MD
Everyday Urology-Oncology Insights: Volume 2, Issue 1

More than 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases which leads to a significant increase in morbidity and mortality.1,2  Patients with metastatic prostate cancer and bone involvement have only a 3% five-year survival, whereas the five-year survival of patients without bone metastases is 56%. Skeletal-related events (SRE) in mCRPC patients may cause potentially devastating effects, such as decreased survival and pain, impaired mobility and spinal cord compression.2 Bone metastases and SREs diminish a patient’s quality of life and increase medical costs.3,4  
By Neal Shore, MD, FACS
Prostate cancer is the most common malignancy among US men, with an estimated annual incidence of 180,890, accounting for one in five new cancer cases in men [1]. The second-most common cause of cancer death in US men, prostate cancer is expected to claim the lives of 26,120 men in this country in 2016 [1]. For men with castration-resistant prostate cancer (CRPC), median survival ranges from nine to 34 months, depending upon numerous factors, including but not limited to, the presence of metastases, the location and  volume of metastases, the presence of co-morbidities, the degree of acknowledged and interrogated symptomatology, etc.  [2]. 
Library Resources
Evidence based monographs by experts to define and guide clinical practice
Written by Christopher J.D. Wallis, MD, PhD and Zachary Klaassen, MD, MSc
Prostate cancer exhibits a wide spectrum of disease behaviour. Despite the majority of cases presenting with relatively indolent biologic behaviour, prostate cancer remains the second leading cause of cancer-related death in the United States, behind only lung cancer.
Conference Coverage
Recent data from conferences worldwide
Presented by Silke Gillessen, MD
San Francisco, CA ( Silke Gillessen, MD presented a study comparing two different dosing frequencies of Denusomab in patients with castration-resistant prostate cancer, and evaluating the rate of hypocalcemia in these two treatment options.
Presented by Matthew R. Smith, MD, Ph.D.
Munich, Germany ( Radium-223 is an alpha emitter which selectively treats bone metastases with alpha radiation.1 In a recent GU ASCO oral presentation, a radium-223 pharmacodynamic study demonstrated
Presented by Matthew R. Smith, MD, Ph.D.
Munich, Germany ( As has been the trend in management of advanced solid malignancies, there has been increasing interest 

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.